Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence
| Autor: | Shinichi Tate, Ayumu Matsuoka, Kyoko Nishikimi, Makio Shozu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Bevacizumab Urology Aggressive surgery 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Surgical oncology medicine Humans Stage (cooking) Peritoneal Neoplasms Aged Retrospective Studies Ovarian Neoplasms business.industry Hematology General Medicine Middle Aged medicine.disease Confidence interval 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Female Surgery Lymph Nodes Lymph Neoplasm Recurrence Local business Ovarian cancer medicine.drug Fallopian tube |
| Zdroj: | International Journal of Clinical Oncology. 25:1726-1735 |
| ISSN: | 1437-7772 1341-9625 |
| DOI: | 10.1007/s10147-020-01714-w |
| Popis: | This study investigated the pattern of first recurrence of advanced ovarian cancer before and after the introduction of aggressive surgery. We investigated 291 patients with stage III/IV epithelial ovarian, fallopian tube, and peritoneal cancer. Aggressive surgery including gastrointestinal and upper abdominal surgeries was introduced for advanced ovarian cancer in 2008. The site and time until first recurrence were compared between 70 patients treated without aggressive surgery (2000–2007) and 221 patients who underwent aggressive surgery (2008–2016). The intraperitoneal recurrence rate was significantly lower in patients treated during 2008–2016 than in patients treated during 2000–2007 (55% [82/149] vs. 81% [46/57], p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink